思 胡大一 祝善俊 顾复生 戚文航 黄峻 蔡廼绳 戴闺柱
专家组成员（按姓氏笔画排序）：马长生 马爱群 方全 王风芝 王学峰 孙超峰 刘晓惠 刘晓方 李小鹰 李为民 李东野 李新立 李隆贵 朱建华 华伟 张运 沈卫峰 吴学思 严激 林曙光 周京敏 柯文南 胡大一 高润霖 黄岚 黄峻 黄从新 黄德嘉 蒋学俊 傅向华 葛均波 韩雅玲 廖玉华 霍勇
利益冲突声明：本指南制定过程中，天津武田药品有限公司、美敦力（上海）有限公司和诺华制药有限公司赞助了会议
参考文献
[1] Colluci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997,
80（11A）: 15L～25L.
[2] Braunwald E，Bristow MR. Congestive heart failure: fifty years of progress. Circulation,
2000, 102（20）: IV-14-23.
[3] Hunt SA,Abraham WT,Chin MH, et al. ACC/AHA 2005 Guideline Update for the diagnosis and
Management of Chronic Heart Failure in the Adult. Circulation, 2005, 112(12): e154-235.
[4] Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults.
Am J Respir Crit Care Med, 1998; 158（5）:1384.
[5] Troosters, T, Gosselink, R, Decramer, M. Six minute walking distance in healthy elderly
subjects. Eur Respir J, 1999, 14(2):270-274.
[6] Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart
failure: what's next? Circulation, 2002, 105 (20):2392-2397.
[7] Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea
in the emergency department (PRIDE) study. Am J Cardiol, 2005, 95(8): 948-954.
[8] Sullivan MJ, Hawthorne MH. Nonpharmacologic Interventions. in: Poole- Wilson PA, Colucci
WS, Massie BM, Chatterjeek, Coats Ajseds. Heart Failure. USA: Churchill Livingstone. 1997: 617-633.
[9] Faris R, Flather M, Purcell H, et al. Current evidence supporting the role of diuretics
in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol, 2002, 82（2）:149–158.
[10] Henry K and Peter C. Diuretics in the treatment of heart failure: Mainstay of therapy or
potential hazard? Editorial Comment. J Card Failure, 2006;12:333–334.
[11] Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the
response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.N Engl J Med ,1998,339:1285-1292.
[12] Garg R, Yusuf S. Overview of randomized trials of angiotensinconverting enzyme inhibitors
on mortality and morbidity in patients with heart failure. JAMA, 1995, 273:1450-1456.
[13] Flather M, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart
failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitor Myocardial Infarction Collaborative Group. Lancet , 2000, 355:1575-1581.
[14] Bristow MR. ?-adrenergic receptor blockade in chronic heart failure. Circulation，2000，
101(5)：558~569.
[15] ESC guidelines for chronic heart failure: 2005 update. Eur Heart J, 2005, 26: 1115~1140. [16] Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic
dilated cardiomyopathy. Lancet, 1993, 342:1441-1446.
26
[17] Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization
of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.Circulation, 2005, 112 (16): 2426-2435.
[18] Hood WB, Dans AL, Guyatt GH, et al. Digitails for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and mata-analysis. J Card Fail, 2004, 10（2）: 155-164.
[19] Rathore SS，Curtis JP，Wang Y ,et al. Association of serum digoxin concentration and outcomes
in patieonts with heart failuie. JAMA, 2003, 289（7）: 871-878.
[20] Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on mortality and morbidity
in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999, 341(10): 709-717.
[21] Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients
with left ventricular dysfunction after myocardial infarction. N Engl J Med, 2003, 348(14): 1309-1321.
[22] Konstam MA, Neaton JD, Poole-Wilson PA, et al. Comparison of losartan and captopril on heart
failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). Am Heart J, 2005, 150(1): 123- 131.
[23] Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee. Effects of losartan and
captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet, 2002, 360(7335):752-760.
[24] Granger CB，McMurray JJV，Yusuf S, et al. Effects of candesartan in patients with chronic
heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors：the CHARM-alternative Trial. Lancet, 2003, 362 (9386): 772-6.
[25] Cohn JN. Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart
Failure Trial. Cardiology. 1999;91 Suppl 1:19-22.
[26] McMurray JJV，Ostergren J， Swedberg K，et al. Effects of candesartan in patients with chronic
heart
failure
and
reduced
left
ventricular
systolic
function
taking
angiotensin-converting-enzyme inhibitors：the CHARM-added Trial. Lancet, 2003, 362 (9386): 767-71.
[27] McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on
atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).J Am Coll Cardiol, 2006, 47(4):726-733.
[28] Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity
and mortality in heart failure. N Engl J Med, 2005, 352(12): 1539-1549.
[29] 中华医学会心电生理和起搏分会. 心脏再同步治疗慢性心力衰竭的建议. 中华心律失常学杂志,
2006, 10(2): 90-102.
[30] Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-Resynchronization Therapy with or without
an Implantable Defibrillator in Advanced Chronic Heart. N Engl J Med, 2004, 350(21):2140-2150.
[31] 中华医学会心血管病分会，中华心血管病杂志编辑委员会：慢性收缩性心力衰竭治疗建议. 中华心
血管病杂志, 2002, 30（1）:7-23.
[32] Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society. Canadian Cardiovascular
27
Society consensus conference recommendations on heart failure 2006: diagnosis and management.Can J Cardiol, 2006, 22(1):23-45.
[33] Heart Failure Society Of America. HFSA 2006 Comprehensive Heart Failure Practice
Guideline.J Card Fail, 2006;12(1):e1-2.
[34] Bonow RO,Carabello B,de Leon AC,et al. ACC/AHA 2006 guidelines for the management of
patients with valvular heart disease：Executive summary. Circulation, 2006, 114（5）：450-527.
[35] The Task Force on the Management of Valvular Heart Dease of the European Society: Guidelines
on the Management of Valvular Heart Dease. Eur Heart J, 2007, 28: 230-268.
[36] The Cardiac Insufficiency Bisoprelol Study II (CIBIS-II): a randomised trial. Lancet,
1999, 353（9146）:9-13.
[37] Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter- defibrillator
for congestive heart failure. N Engl J Med, 2005, 352(3): 225-237.
[38] Valentin Fuster, Lars E Ryden, David S Cannom et al. ACC/AHA/ESC 2006 guidelines for the
management of patients with Atrial Fibrilltion Executive Summary. Circulation, 2006, 114:700-752.
[39] Philbin EF, Santella RN, Rocco TA Jr. Angiotensin-converting enzyme inhibitor use in older
patients with heart failure and renal dysfunction. J Am Geriatr Soc, 1999, 47(3): 302-308.
[40] Singh SN, Fisher SG, Deedwania PC, et al. Pulmonary effect of amiodarone in patients with
heart failure: the Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). J Am Coll Cardiol, 1997, 30(2):514-517.
[41] Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in
patients with moderate to severe chronic heart failure. Circulation, 2003, 107(2):294-299.
[42] Executive summary of the guidelines on the diagnosis and treatment of acute heart
failure.The task force on acute heart failure of European society of cardiology. Eur Heart J,2005,26:384-416.
28
2007中国慢性心力衰竭诊断治疗指南（终稿）
